Protagonist Therapeutics, Inc.
Status: Publicly traded
Direct answer
Protagonist Therapeutics, Inc. is publicly traded on NASDAQ under the ticker PTGX.
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of...
Can you invest in Protagonist Therapeutics, Inc.?
Yes. Protagonist Therapeutics, Inc. trades publicly on NASDAQ as PTGX.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Protagonist Therapeutics, Inc.
Detailed equity research is provided by MarketSnap.